Semaglutide vs Tirzepatide for PCOS: Which Should You Choose?

If you have PCOS and are considering a GLP-1 receptor agonist for the weight and insulin-resistance components, the practical choice usually comes down to two medications: semaglutide and tirzepatide. Both are FDA-approved for chronic weight management in the general adult population (under different brand names), both are used off-label in PCOS, and both have growing PCOS-specific evidence bases. They are not interchangeable. Choosing between them is a real clinical decision with real consequences for outcomes, side effects, and cost.

This post is the head-to-head. We will compare the medications on mechanism, PCOS-specific evidence, weight-loss magnitude, secondary endpoints (insulin, androgens, cycles), side effects, dosing, and cost. The goal is to give you enough framework that the conversation you have with your clinician about which medication to start is a real conversation, not a one-sided pitch.

Mechanism — same family, different details

Semaglutide is a single-receptor agonist: it binds and activates the GLP-1 receptor. The downstream effects are familiar — glucose-dependent insulin secretion, suppressed glucagon, slowed gastric emptying, and central appetite suppression. Semaglutide is administered as a weekly subcutaneous injection.

Tirzepatide is a dual-receptor agonist: it binds and activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is the other major incretin hormone. The two-receptor mechanism produces somewhat larger effects on weight loss and glucose handling than GLP-1 alone — head-to-head trials in type 2 diabetes and in obesity (without PCOS) have consistently shown tirzepatide outperforming semaglutide on weight loss and glycemic markers.

In PCOS specifically, the mechanism question is whether the dual-receptor activation adds anything beyond the insulin-resistance and weight effects you would get from semaglutide alone. The honest answer is: probably, in patients who tolerate the higher doses, but the PCOS-specific head-to-head dataset is still small. The general weight-loss and glucose data suggests yes. The PCOS-specific endpoints (androgens, cycles, ovulation) likely follow the same direction at larger magnitude, given that both medications work through improving insulin sensitivity and producing weight loss.

Weight loss — where the magnitudes differ

In general-population trials, semaglutide produces approximately 15–17% body-weight reduction at maximum tolerated dose over 68 weeks. Tirzepatide produces approximately 20–22% over similar durations. That difference is real and consistent across trial after trial.

In PCOS specifically, the most striking dataset to date is the UK real-world tirzepatide cohort: 4,241 women with PCOS prescribed tirzepatide between February 2024 and January 2025. Median weight loss was 18.81% at ten months, with 90.8% reaching at least 10% loss and 75.96% reaching at least 15%. That cohort is large enough — and the response rate consistent enough — to set a useful expectation: if you have PCOS and you stay on tirzepatide for ten months at therapeutic dose, the average outcome is ~18-19% body weight reduction.

Semaglutide PCOS-specific cohorts and trials have typically reported 10–15% weight loss at six months — a different timeframe and a different magnitude. The Jensterle 2023 RCT (16 weeks, 1.0 mg weekly) and subsequent semaglutide PCOS studies have shown smaller weight loss than the UK tirzepatide cohort, partly because the trial durations were shorter and partly because the medication produces less weight loss on average. Both medications work; the magnitude differs.

For a patient with significant weight to lose, that magnitude difference can matter clinically. For a patient near a healthy BMI who is on GLP-1 primarily for insulin and cycle benefits, the magnitude is less central — and the choice might lean toward semaglutide on tolerability or cost.

Secondary endpoints — insulin, androgens, cycles

Both medications improve insulin sensitivity, reduce free testosterone, and improve menstrual regularity in PCOS patients. The Cena et al. 2024 meta-analysis pooled five PCOS trials and reported approximately 28% reduction in free testosterone, approximately 68% improvement in menstrual regularity, approximately 31% improvement in HOMA-IR, and ovulation rates rising approximately 55% across the studied medications.

The pooled data is mostly semaglutide and liraglutide because the PCOS-specific tirzepatide trial dataset is still being published. What can be said with confidence:

• Insulin sensitivity: Both medications produce meaningful improvements in HOMA-IR and fasting insulin in PCOS patients. Tirzepatide's GIP-receptor activation may give it a slight edge in glucose handling, especially in patients with concurrent prediabetes or type 2.
• Free testosterone: Both medications reduce free testosterone, mediated through insulin reduction and SHBG increase. The magnitude scales with the magnitude of weight loss and insulin improvement.
• Cycle regularity: Both improve cycle regularity. The largest improvements concentrate in patients who reach ≥10% body-weight loss — and that bar is reached more often, and faster, on tirzepatide.

If your PCOS phenotype is dominated by metabolic dysfunction (high HOMA-IR, prediabetes, significant weight), the case for tirzepatide is stronger on first principles — its dual mechanism is more aggressive on the metabolic axis. If your PCOS phenotype is dominated by androgens with milder metabolic features, both medications work and the choice tilts on tolerability and cost.

Side effects — same class, slight pattern differences

The side-effect profile is the same class profile: nausea (20–40% across both medications), occasional vomiting and constipation, slowed gastric emptying, rare gallbladder events, rare pancreatitis, and the boxed warning for medullary thyroid carcinoma in patients with personal or family MEN-2 history. Neither medication is appropriate during pregnancy or breastfeeding.

Real-world experience suggests some pattern differences:

• Tirzepatide users frequently describe somewhat better tolerability at low doses than semaglutide users at comparable points in titration — possibly because the dual-receptor mechanism produces a different curve of GI effects.
• Tirzepatide at higher doses (12.5 mg, 15 mg) can produce more pronounced nausea than semaglutide at comparable trial-curve doses.
• The slowed gastric emptying is more pronounced on the higher tirzepatide doses, which is relevant to oral contraceptive absorption (more on this below).

For PCOS patients on oral contraceptives, both medications can reduce OCP absorption due to delayed gastric emptying. Current guidance is to use a back-up barrier method during dose escalation. This is true for both semaglutide and tirzepatide, but the magnitude of the gastric-emptying effect is somewhat larger on higher tirzepatide doses, so the contraception conversation matters more there.

Cost — direct-pay reality

Brand-name pricing in the U.S. for semaglutide and tirzepatide products is in the $1,000–1,300 per month range without insurance, and insurance coverage for off-label PCOS use is rare. The direct-pay compounded path has been the practical access point for most PCOS patients.

At TelePeptide, compounded semaglutide is $149 per month and compounded tirzepatide is $199 per month, both at founder-rate pricing. Those prices include the medication; clinician visits, labs, and supplies are separate (or included in the program depending on the tier). The $50 monthly difference between the two medications is real but small relative to the brand pricing it replaces. For most patients the choice is not driven by the price gap — it is driven by the magnitude of weight loss needed, side-effect tolerance, and what the clinician thinks fits the individual.

Compounded medications are prepared by licensed 503A pharmacies under individual prescriptions. They are not FDA-approved and are not equivalent to the brand-name FDA-approved drugs.

How clinicians choose

The clinical choice between semaglutide and tirzepatide for PCOS is rarely formulaic. The factors that move the decision in our experience:

1. Magnitude of weight loss needed. If the patient is significantly above their target weight and the goal is to reach the ≥10% body-weight threshold where the largest PCOS benefits cluster, tirzepatide's larger effect size makes it the more efficient tool. If the patient is only moderately overweight or has a lean PCOS phenotype, semaglutide is often sufficient.

2. Side-effect history. Patients who have tolerated semaglutide poorly in the past sometimes do better on tirzepatide and vice versa. There is no reliable predictor — both medications get tried in real-world practice.

3. Concurrent prediabetes or type 2. Tirzepatide's dual-receptor activation has produced larger glycemic improvements in head-to-head trials. If glucose is a significant part of the picture, the clinician usually leans tirzepatide.

4. TTC timeline. Both medications require a washout before conception. Semaglutide's washout guidance is at least eight weeks before a planned pregnancy; tirzepatide's is approximately four to five weeks. If TTC is on the near horizon (six to twelve months out), the shorter washout may modestly favor tirzepatide on that one dimension. But the broader fertility planning conversation matters more than the washout difference alone.

5. Cost sensitivity. If the $50 monthly difference matters to the patient's budget, semaglutide is the cheaper option and is fully appropriate for the majority of PCOS patients.

6. Microdose appropriateness. Both medications can be used at microdose levels. Semaglutide microdosing has a longer informal track record — that may be a marginal factor for patients pursuing the gentlest possible on-ramp.

A reasonable default

In the absence of strong individual factors pulling one direction, a reasonable default for a PCOS patient with significant weight to lose and a metabolic-dominant phenotype is to start with tirzepatide — the magnitude data is the strongest, the metabolic mechanism is the most aggressive, and the real-world PCOS cohort is the largest.

For a PCOS patient with mild metabolic dysfunction, near-normal weight, or significant cost sensitivity, semaglutide is the more conservative and equally clinically reasonable choice — and is the medication with the longer PCOS-specific track record.

There is no wrong answer in most cases. There is a better-fit answer for the individual patient, which is the conversation to have with your clinician.

---

This article is for education, not medical advice. Whether semaglutide or tirzepatide is appropriate for your PCOS depends on your individual clinical picture — weight, labs, history, fertility goals, and side-effect tolerance. The decision is made by you and a licensed clinician.